SUTRO BIOPHARMA, INC. Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss
SUTRO BIOPHARMA, INC. (STRO) had Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss of $85.70 million as of 2021-09-30, per its 10-Q filed 2021-11-10.
Discontinued › Notes
us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss · last filed 2021-11-10
- 2021-09-30: Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss $85.70M.
- 2021-06-30: Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss $93.80M.
- 2021-03-31: Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss $84.60M.
- 2020-12-31: Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss $14.70M.
| Period end | Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss |
|---|---|
| 2021-09-30 | $85.70M 10-Q · filed 2021-11-10 |
| 2021-06-30 | $93.80M 10-Q · filed 2021-08-09 |
| 2021-03-31 | $84.60M 10-Q · filed 2021-05-07 |
| 2020-12-31 | $14.70M 10-Q · filed 2021-11-10 |
| 2020-09-30 | $0.00 10-Q · filed 2020-11-05 |
| 2020-06-30 | $25.00M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $48.50M 10-Q · filed 2020-05-11 |
| 2019-12-31 | $4.50M 10-K · filed 2021-03-18 |
| 2019-09-30 | $20.10M 10-Q · filed 2019-11-08 |
| 2019-06-30 | $13.00M 10-Q · filed 2019-08-14 |
| 2018-12-31 | $52.60M 10-K · filed 2020-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 |